Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Assets (2016 - 2025)

Tg Therapeutics has reported Assets over the past 10 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly results put Assets at $1.1 billion for Q4 2025, up 84.05% from a year ago — trailing twelve months through Dec 2025 was $1.1 billion (up 84.05% YoY), and the annual figure for FY2025 was $1.1 billion, up 84.05%.
  • Assets for Q4 2025 was $1.1 billion at Tg Therapeutics, up from $1.0 billion in the prior quarter.
  • Over the last five years, Assets for TGTX hit a ceiling of $1.1 billion in Q4 2025 and a floor of $193.6 million in Q4 2022.
  • Median Assets over the past 5 years was $390.4 million (2021), compared with a mean of $462.5 million.
  • Biggest five-year swings in Assets: skyrocketed 438.74% in 2021 and later plummeted 49.01% in 2022.
  • Tg Therapeutics' Assets stood at $379.6 million in 2021, then plummeted by 49.01% to $193.6 million in 2022, then skyrocketed by 70.27% to $329.6 million in 2023, then skyrocketed by 75.28% to $577.7 million in 2024, then soared by 84.05% to $1.1 billion in 2025.
  • The last three reported values for Assets were $1.1 billion (Q4 2025), $1.0 billion (Q3 2025), and $702.6 million (Q2 2025) per Business Quant data.